Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07690163). This is a study registration, not published results. Lead sponsor: Nazarii Kobyliak. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 80 participants (ESTIMATED). Conditions: Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Insulin Resistance. Interventions: DEVICE: CGM Sibionics; DEVICE: On-Call Extra Glucometer. Primary outcome measures: Changes in HbA1c level , at 3 month (end of follow-up period); Changes in Fructosamine level , at 1 month (end of intervention period). Brief summary: This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University. Participants may be lifestyle-controlled or receiving stable non-insulin anti-diabetic medications. Participants will be randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring group (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \[SMBG\] using conventional glucometers). The gathered data will help determine whether the real-time visual feedback provided by CGM systems superiorly improves glycemic variability, optimizes metabolic parameters, and enhances patient adherence to lifestyle interventions and pharmacological treatment compared to conventional SMBG methods in the early stages of T2D.